Q-omics provides the consensus-scored PDE10A profile across patient tissues and cancer cell-line models. PDE10A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PDE10A is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PDE10A RNA expression shows 18,497 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where PDE10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PDE10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PDE10A survival associations across molecular data types. PDE10A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PDE10A RNA expression–survival associations across cancer types. High PDE10A expression shows unfavorable associations in MESO, ACC, LUAD, KIRP, STAD and UVM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PDE10A RNA expression.
This table summarizes PDE10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PDE10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PDE10A shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in HNSC, COAD and CHOL. The HNSC box plot shows higher PDE10A RNA expression in tumor versus normal tissue (log2 FC = +0.588, t-test p < 0.001).
This table shows molecular features associated with PDE10A in patient tissues and cancer cell lines. In patient samples, PDE10A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PDE10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
